42.10
0.59%
-0.25
Cerevel Therapeutics Holdings Inc 주식(CERE)의 최신 뉴스
INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerevel Therapeutics and AbbVie for Unfair Process - ForexTV.com
ForexTV.com
INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerevel ... - GlobeNewswire
GlobeNewswire
Market Recap Check: Cerevel Therapeutics Holdings Inc (CERE)'s Positive Finish at 42.31, Up/Down 0.17 – DWinneX - The Dwinnex
The Dwinnex
Recent Insider Activity Could Benefit Cerevel Therapeutics Holdings Inc (CERE) – Knox Daily - Knox Daily
Knox Daily
Insider Selling: Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Director Sells 50,000 Shares of Stock - MarketBeat
MarketBeat
Insider Selling: Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Director Sells 50,000 Shares of Stock - MarketBeat
MarketBeat
AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
Zacks Investment Research
CEREVEL THERAPEUTICS HOLDINGS, INC. (NASDAQ: CERE) INVESTIGATION ALERT: Is $45 per CERE Share ... - GlobeNewswire
GlobeNewswire
Versor Investments LP Invests $4.61 Million in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) - MarketBeat
MarketBeat
20,300 Shares in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Bought by Kellner Capital LLC - MarketBeat
MarketBeat
Segantii Capital Management Ltd Acquires Shares of 594,519 Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) - MarketBeat
MarketBeat
One Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) insider upped their stake by 148% in the previous year - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Exclusive-AbbVie nears roughly $8 billion deal for drug developer Cerevel-sources - Yahoo Movies Canada
Yahoo Movies Canada
International Assets Investment Management LLC Invests $23.37 Million in Cerevel Therapeutics Holdings, Inc ... - MarketBeat
MarketBeat
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Given Average Rating of "Hold" by Analysts - MarketBeat
MarketBeat
CERE's Stock Market Pendulum: Swinging Between Gains and Losses – Invest Chronicle - The InvestChronicle
The InvestChronicle
CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings, Inc ... - GlobeNewswire
GlobeNewswire
CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings, Inc ... - GlobeNewswire
GlobeNewswire
Cerevel's Parkinson's success is music to AbbVie's ears - The Pharma Letter
The Pharma Letter
A company insider recently sold 50000 shares of Cerevel Therapeutics Holdings Inc [CERE]. Should You Sale? – Knox ... - Knox Daily
Knox Daily
Parkinson's Results Further Sweeten AbbVie's Acquisition of Cerevel - Scrip
Scrip
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
GlobeNewswire Inc.
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living ... - GlobeNewswire
GlobeNewswire
Neumora Tumbles as Early-Stage Study Put on Clinical Hold - Bloomberg
Bloomberg
Neurosterix emerges with $63m for neuroscience pipeline - pharmaphorum
pharmaphorum
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
Zacks Investment Research
Strike While The Market Is Hot
Seeking Alpha
30 Biggest Biotechnology Companies in the World - Insider Monkey
Insider Monkey
Cerevel Therapeutics: Parkinson's Could Be The Issue (NASDAQ:CERE) - Seeking Alpha
Seeking Alpha
Minerva setback doesn't preclude big year for schizophrenia - BioCentury
BioCentury
Is AbbVie Stock a Buy Now?
The Motley Fool
AbbVie Eyes $13 Billion Bond Sale to Finance Acquisitions: A Deep Dive into the Strategic Move - Medriva
Medriva
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
Zacks Investment Research
AbbVie Eyes Selling at Least $13 Billion of Bonds to Fund M&A - Bloomberg
Bloomberg
AbbVie taps new CEO as it faces fresh competition for blockbuster drug Humira
MarketWatch
AbbVie's Cerevel deal hits an uncommon roadblock - Yahoo Finance
Yahoo Finance
Cerevel Therapeutics Advances in Merger Amid FTC Review - TipRanks.com - TipRanks
TipRanks
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
Benzinga
Cerevel, AbbVie get FTC Second Requests for more merger info (NASDAQ:CERE) - Seeking Alpha
Seeking Alpha
AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen
MarketWatch
AbbVie Cuts Its Guidance on ImmunoGen Deal - Investopedia
Investopedia
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
Benzinga
AbbVie’s fourth-quarter sales top estimates despite plunging Humira revenues
MarketWatch
AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp ... - GlobeNewswire
GlobeNewswire
Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024 - BioCentury
BioCentury
Karuna, Cerevel might be just the start of psychiatry drug M&A - Yahoo Finance
Yahoo Finance
Is AbbVie Stock a Buy Now?
The Motley Fool
JP Morgan Maintains Neutral Rating for Cerevel Therapeutics Hldg: Here's What You Need To Know
Benzinga
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
Zacks Investment Research
자본화:
|
볼륨(24시간):